p53 Modulates Radiosensitivity in Head and Neck Cancers—From Classic to Future Horizons

p53, initially considered a tumor suppressor, has been the subject of research related to cancer treatment resistance in the last 30 years. The unfavorable response to multimodal therapy and the higher recurrence rate, despite an aggressive approach, make HNSCC a research topic of interest for impro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diagnostics (Basel) Jg. 12; H. 12; S. 3052
Hauptverfasser: Mireștean, Camil Ciprian, Iancu, Roxana Irina, Iancu, Dragoș Petru Teodor
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI AG 01.12.2022
MDPI
Schlagworte:
Apoptosis
Biomarkers
Cancer therapies
Care and treatment
Cell cycle
Cell division
Chemotherapy
DNA damage
Head & neck cancer
Head and neck cancer
head and neck cancers
Health aspects
HNSCC
Kinases
Metabolism
Methods
Mutation
Ovarian cancer
p53
Phase transitions
Radiation
radioresistance
radiosensitivity
Radiotherapy
Review
Tumor proteins
Tumors
Romania
radiotherapy
head and neck cancers
HNSCC
radioresistance
radiosensitivity
p53
ISSN:2075-4418, 2075-4418
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:p53, initially considered a tumor suppressor, has been the subject of research related to cancer treatment resistance in the last 30 years. The unfavorable response to multimodal therapy and the higher recurrence rate, despite an aggressive approach, make HNSCC a research topic of interest for improving therapeutic outcomes, even if it is only the sixth most common malignancy worldwide. New advances in molecular biology and genetics include the involvement of miRNA in the control of the p53 pathway, the understanding of mechanisms such as gain/loss of function, and the development of different methods to restore p53 function, especially for HPV-negative cases. The different ratio between mutant p53 status in the primary tumor and distant metastasis originating HNSCC may serve to select the best therapeutic target for activating an abscopal effect by radiotherapy as a “booster” of the immune system. P53 may also be a key player in choosing radiotherapy fractionation regimens. Targeting any pathway involving p53, including tumor metabolism, in particular the Warburg effect, could modulate the radiosensitivity and chemo-sensitivity of head and neck cancers.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics12123052